Brief: Amphastar Pharmaceuticals Enteres License Agreement With Nanjing Anji Biotechnology
12/08/2025 11:47
Aug 12 (Reuters) - Amphastar Pharmaceuticals Inc AMPH.O: AMPHASTAR PHARMACEUTICALS INC - ON AUGUST 8, ENTERED LICENSE AGREEMENT WITH NANJING ANJI BIOTECHNOLOGY - SEC FILING AMPHASTAR PHARMACEUTICALS INC - TO PAY UP TO $267 MILLION IN MILESTONE PAYMENTS - SEC FILING AMPHASTAR PHARMACEUTICALS INC - PAYS $6 MILLION TO ANJI UPON AGREEMENT SIGNING - SEC FILING Further company coverage: AMPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amphastar Pharmaceuticals,
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Amphastar Q1 revenue and adjusted EPS miss estimates
Brief: Amphastar Pharmaceuticals Q1 EPS USD 0.14
Brief: Amphastar Pharmaceuticals Inc - Authorizes $50 Million Increase To Share Buyback Program On March 12, 2026 - SEC Filing
Brief: Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing